Astellas Pharma (JP:4503) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Astellas Pharma Inc. reported a foreign exchange loss of ¥12.2 billion for the first half of FY2024, following fluctuations in currency rates that led to a significant loss in the second quarter despite gains in the first quarter. These financial results highlight the impact of currency valuations on the company’s monetary assets and liabilities.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.